Studio City Finance Limited Announces Pricing of Senior Notes Offering
05 janv. 2021 13h11 HE
|
Studio City
MACAU, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Studio City Finance Limited (“Studio City Finance”) today announces that it has priced its international offering of senior notes due 2029 (the “New Notes”...
Studio City Finance Limited Announces Proposed Senior Notes Offering and Conditional Tender Offer
04 janv. 2021 07h07 HE
|
Studio City
MACAU, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Studio City Finance Limited (“Studio City Finance”) today announces that it proposes to conduct an international offering of senior notes (the “New Notes”...
Bone Therapeutics SA : Finalisation de l’acquisition de SCTS, sa filiale de production de thérapie cellulaire, par Catalent
16 nov. 2020 01h00 HE
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Gosselies, Belgique, le 16 Novembre 2020, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement...
Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent
16 nov. 2020 01h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION Gosselies, Belgium, 16 November 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics...
Studio City International Holdings Limited Announces Unaudited Third Quarter 2020 Earnings
05 nov. 2020 08h08 HE
|
Studio City
MACAU, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Studio City International Holdings Limited (NYSE: MSC) (“Studio City” or the “Company”), a world-class integrated resort located in Cotai, Macau, today...
Studio City Announces Earnings Release Date
29 oct. 2020 07h13 HE
|
Studio City
MACAU, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Studio City International Holdings Limited (NYSE: MSC), a world-class integrated resort located in Cotai, Macau, today announces that it will furnish its...
Bone Therapeutics signe des accords avec Catalent pour optimiser la production du produit de thérapie cellulaire allogénique ALLOB
29 oct. 2020 02h00 HE
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Catalent acquiert la chaine de production de thérapie cellulaire de Bone Therapeutics pour 12 M€ Signature en parallèle d’un accord d’approvisionnement entre Bone...
Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
29 oct. 2020 02h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION Catalent to acquire Bone Therapeutics’ cell therapy manufacturing facility for EUR 12 million Bone Therapeutics and Catalent shall enter into a supply agreement for...
Bone Therapeutics: Le produit de thérapie cellulaire allogénique, ALLOB, montre un taux de fusion des vertèbres lombaires de 90% à 24 mois dans l’étude de phase IIa
14 oct. 2020 01h00 HE
|
Bone Therapeutics SA
90% des patients présentent une fusion osseuse ainsi que de fortes améliorations cliniques de la capacité fonctionnelle et de la réduction de la douleur, à 24 mois de suivi, avec un bon profil de...
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
14 oct. 2020 01h00 HE
|
Bone Therapeutics SA
90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up period with a good product safety profile Gosselies, Belgium, 14 October...